Maraviroc exposure is influenced by exogenous thyrotoxicosis
Résumé
Maraviroc (MVC) is a noncompetitive antagonist of CCR5 that inhibits HIV replication in treatment-experienced and treatment-naïve patients. MVC is considered to be safe and is part of the HIV armamentarium.
MVC is a substrate of CYP3A4/5 and P-gp, which account for most of MVC pharmacokinetic variability related to drug–drug interactions (DDI). In the combined antiretroviral therapy (cART) era, ageing of HIV patients is associated with an increased likelihood of comorbidities and related comedications. In that line, hypothyroidism is frequent and patients may require levothyroxine supplementation to restore euthyroidism.